(0.17%) 5 140.00 points
(0.12%) 38 487 points
(0.25%) 17 891 points
(-0.23%) $83.66
(0.94%) $1.941
(0.26%) $2 353.20
(0.52%) $27.68
(1.83%) $938.95
(-0.17%) $0.933
(-0.31%) $10.99
(-0.30%) $0.798
(1.18%) $92.96
Live Chart Being Loaded With Signals
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa...
Stats | |
---|---|
今日成交量 | 476 022 |
平均成交量 | 382 840 |
市值 | 1.39M |
EPS | $0 ( 2024-02-16 ) |
下一个收益日期 | ( $0 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.550 |
ATR14 | $0.00400 (1.74%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-14 | Hull Andrew | Sell | 42 | Employee Stock Option (Expiration) |
2024-03-04 | Hsu Eric C | Sell | 309 | Employee Stock Option (Expiration) |
2024-01-21 | Mancini Alexandra Diane Janet | Sell | 121 | Employee Stock Option (Expiration) |
2024-02-20 | Jagpal Netta | Sell | 50 000 | Employee Stock Option (Right to Buy) |
2024-02-21 | Hull Andrew | Buy | 37 500 | Common Stock |
INSIDER POWER |
---|
74.61 |
Last 93 transactions |
Buy: 1 291 573 | Sell: 391 310 |
音量 相关性
InMed Pharmaceuticals 相关性 - 货币/商品
InMed Pharmaceuticals 财务报表
Annual | 2023 |
营收: | $4.14M |
毛利润: | $1.40M (33.93 %) |
EPS: | $-3.25 |
FY | 2023 |
营收: | $4.14M |
毛利润: | $1.40M (33.93 %) |
EPS: | $-3.25 |
FY | 2022 |
营收: | $1.09M |
毛利润: | $543 546 (49.89 %) |
EPS: | $-41.74 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-38.00 |
Financial Reports:
No articles found.
InMed Pharmaceuticals
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。